REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 63RD ANNUAL MEETING, HONOLULU, HAWAII, APRIL 9-16, 2011 – The possible link between Alzheimer’s disease and a history of traumatic brain injury is unclear (for a review see Jellinger KA. Curr Opin Neurol 2004; 17: 719-723). This issue was examined in a retrospective analysis of pathology data for the period 1997 to 2010 (Mehta et al. AAN 2011; abstract P07.244). Traumatic brain injury was defined as a closed head injury with loss of consciousness. The study sample included 108 subjects with AD, of whom 11 had a history of brain injury.
Latest News
First report of increased risk of prostate cancer in PD
June 29, 2011REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 63RD ANNUAL MEETING, HONOLULU, HAWAII, APRIL 9-16, 2011 – Epidemiological studies have suggested that cancer risk is generally lower in PD patients compared to those without PD (11% vs. 14%), including a lower risk of prostate cancer (RR 0.74) (Driver et al. Cancer Epidemiol Biomarkers Prev 2007; 16: 1260-1265; free full text at http://cebp.aacrjournals.org/content/16/6/1260.long). The risk of certain cancers (e.g. melanoma) may be higher.
Plasma clusterin a possible biomarker of AD severity
June 29, 2011REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 63RD ANNUAL MEETING, HONOLULU, HAWAII, APRIL 9-16, 2011 – Clusterin (apoJ) is a heterodimeric protein that may play a role in amyloid plaque formation by acting as an extracellular chaperone (for a review see Thambisetty M. Biomark 2010; 4: 831-834; free full text at www.futuremedicine.com/doi/abs/10.2217/bmm.10.108).
Increased clusterin levels have been found in the brain and CSF of AD patients, and clusterin gene (CLU) polymorphisms appear to be associated with AD risk (Jun et al. Arch Neurol 2010; 67: 1473-1484).
NMDA antagonists in Parkinson’s disease: meta-analysis
June 29, 2011REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 63RD ANNUAL MEETING, HONOLULU, HAWAII, APRIL 9-16, 2011 – Canadian researchers have conducted a meta-analysis of 11 trials (n=253) of N-methyl-D-aspartate (NMDA) antagonists for peak-dose levodopa-induced dyskinesias in Parkinson’s disease (AAN 2011; abstract P05.098). NMDA receptors are involved in dopamine-glutamate interactions.
The rationale for the use of anti-glutamatergic agents in levodopa-induced dyskinesias is that receptor structure and function are altered by dopamine depletion and pharmacological treatments (Hallett & Standaert. Pharmacol Ther 2004; 102: 155-174).